The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
